永安药业涨2.01%，成交额3957.30万元，主力资金净流入429.45万元

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical has experienced significant stock price fluctuations and changes in financial performance, with a notable increase in stock price year-to-date but a decline in recent trading periods [1][2]. Group 2 - As of December 18, Yong'an Pharmaceutical's stock price increased by 2.01% to 15.25 CNY per share, with a market capitalization of 4.494 billion CNY [1]. - The company has seen a year-to-date stock price increase of 93.23%, but it has declined by 0.20% over the last five trading days, 7.41% over the last 20 days, and 15.79% over the last 60 days [1]. - Yong'an Pharmaceutical has appeared on the trading leaderboard 30 times this year, with the most recent appearance on July 21, where it recorded a net buy of -289 million CNY [1]. Group 3 - For the period from January to September 2025, Yong'an Pharmaceutical reported operating revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 25.4963 million CNY, down 58.78% year-on-year [2]. - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.6649 million CNY distributed over the past three years [3]. Group 4 - Yong'an Pharmaceutical is primarily engaged in the research, production, and sales of taurine products, with taurine accounting for 64.14% of its main business revenue [1]. - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and raw materials, and is associated with various concept sectors including pet economy, pharmaceutical e-commerce, and graphene [1].